Hikma Pharmaceuticals annual profit rises on injectables sales growth

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Pharmaceutical company Hikma Pharmaceuticals reported a rise in profit led by growth in its injectables business.

For the year ended 31 December 2020, pre-tax profit rose to $558 million from $491 million last year and revenue to rise 6% to $2.34 billion.

Injectables revenue was increased by 9% to $977 million, while generics revenue was up 3% and branded up 5% to £613 million.

Looking to 2021, injectables revenue growth was forecast to grow in the mid-single digits, with core operating margin in the range of 37% to 38%; generics revenue in the range of $770 million to $810 million and branded revenue expected to grow in the mid-single digits in constant currency.

At 8:16am: (LON:HIK) Hikma Pharmaceuticals PLC share price was 0p at 2659p